The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The importance of starting treatment early in patients with MDS
Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the importance of early treatment in patients with myelodysplastic syndromes (MDS). Dr Chee advises that patients with symptomatic anemia should start treatment early if possible. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I would say that, you know, there’s been quite a lot of studies showing that if you start treatments, even with erythropoiesis-stimulating agents, and there is another more novel agent, luspatercept, which is also a TGF-β modulator, which is approved in some countries for use. If you start treatment early in the disease course, we tend to get better and longer responses. So I think when patients present with myelodysplasia, if they have symptomatic anemia, it is probably advisable if you have access to start treatment a bit earlier...
I would say that, you know, there’s been quite a lot of studies showing that if you start treatments, even with erythropoiesis-stimulating agents, and there is another more novel agent, luspatercept, which is also a TGF-β modulator, which is approved in some countries for use. If you start treatment early in the disease course, we tend to get better and longer responses. So I think when patients present with myelodysplasia, if they have symptomatic anemia, it is probably advisable if you have access to start treatment a bit earlier. And if they become transfusion dependent, one has to watch the iron stores to make sure that they don’t get iron overloaded otherwise we need to start them on iron chelators because that can also impact their overall outcome.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
